DOP2016000079A - Glicoproteinas recombinantes y sus usos - Google Patents

Glicoproteinas recombinantes y sus usos

Info

Publication number
DOP2016000079A
DOP2016000079A DO2016000079A DO2016000079A DOP2016000079A DO P2016000079 A DOP2016000079 A DO P2016000079A DO 2016000079 A DO2016000079 A DO 2016000079A DO 2016000079 A DO2016000079 A DO 2016000079A DO P2016000079 A DOP2016000079 A DO P2016000079A
Authority
DO
Dominican Republic
Prior art keywords
recombinant
galactosidase
methods
glycoproteins
glicoproteins
Prior art date
Application number
DO2016000079A
Other languages
English (en)
Inventor
Lee Karen
Hwang Christopher
Demaria Christine
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DOP2016000079A publication Critical patent/DOP2016000079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)

Abstract

En la presente se proporcionan glicoproteínas recombinantes (por ejemplo, proteínas de a-galactosidasa-A humana recombinante) con un perfil de glicosilación alterado (por ejemplo, mejorado), y composiciones farmacéuticas y kits que incluyen una o más de esas proteínas. También se proporcionan métodos para generar una célula de mamífero útil para la expresión recombinante de una glicoproteína (por ejemplo, una a-galactosidasa-A humana recombinante), métodos para producir glicoproteínas recombinantes, y métodos de tratamiento que incluyen la administración a un sujeto de al menos una de las glicoproteínas recombinantes (por ejemplo, una proteína de a-galactosidasa-A humana recombinante).
DO2016000079A 2013-10-23 2016-04-11 Glicoproteinas recombinantes y sus usos DOP2016000079A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894879P 2013-10-23 2013-10-23
US201361901942P 2013-11-08 2013-11-08
PCT/US2014/061789 WO2015061464A2 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof

Publications (1)

Publication Number Publication Date
DOP2016000079A true DOP2016000079A (es) 2016-05-30

Family

ID=51871299

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000079A DOP2016000079A (es) 2013-10-23 2016-04-11 Glicoproteinas recombinantes y sus usos

Country Status (33)

Country Link
US (2) US11208644B2 (es)
EP (2) EP3778884A1 (es)
JP (2) JP6837334B2 (es)
KR (2) KR102298080B1 (es)
CN (3) CN114606217A (es)
AU (2) AU2014340152A1 (es)
BR (1) BR112016008086A2 (es)
CA (1) CA2927852A1 (es)
CL (1) CL2016000961A1 (es)
CR (1) CR20160225A (es)
DK (1) DK3060660T3 (es)
DO (1) DOP2016000079A (es)
EA (1) EA034515B1 (es)
ES (1) ES2882562T3 (es)
HR (1) HRP20211197T1 (es)
HU (1) HUE055236T2 (es)
IL (2) IL245255B (es)
LT (1) LT3060660T (es)
MX (1) MX2016005321A (es)
MY (2) MY197247A (es)
NZ (1) NZ720384A (es)
PE (1) PE20160723A1 (es)
PH (1) PH12016500708A1 (es)
PL (1) PL3060660T3 (es)
PT (1) PT3060660T (es)
RS (1) RS62171B1 (es)
SG (2) SG11201602932WA (es)
SI (1) SI3060660T1 (es)
TN (1) TN2016000140A1 (es)
TW (3) TW202332774A (es)
UA (1) UA119857C2 (es)
UY (1) UY35794A (es)
WO (1) WO2015061464A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017201328A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
CA3039673A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
EP1538202B1 (en) * 1996-09-13 2014-01-22 Shire Human Genetic Therapies, Inc. Production of human alpha-galactosidase A
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7133354B2 (en) 2002-08-26 2006-11-07 Qualcomm Incorporated Synchronization techniques for a wireless system
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
EP2134853B1 (en) * 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules
BRPI0815889A2 (pt) * 2007-08-31 2014-10-14 Hoffmann La Roche Análise do perfil de glicosilação.
RU2011142230A (ru) * 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
CN102933707B (zh) * 2010-03-02 2015-09-30 普罗塔里克斯有限公司 稳定的α-半乳糖苷酶及其用途
US20120178105A1 (en) 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
DK2665814T3 (en) * 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
AU2012322811A1 (en) * 2011-10-12 2014-05-01 Synageva Biopharma Corp. Recombinant human NaGlu protein and uses thereof
EP2620506A1 (en) 2012-01-25 2013-07-31 Arla Foods Amba Method of producing a galacto-oligosaccharide-containing composition
TWI528785B (zh) 2013-02-08 2016-04-01 瑞昱半導體股份有限公司 立體影像的調整裝置及其方法
MX2015012114A (es) 2013-03-08 2016-01-12 Genzyme Corp Fabricacion continua integrada de principios activos proteinicos terapeuticos.

Also Published As

Publication number Publication date
US20220064617A1 (en) 2022-03-03
IL272609A (en) 2020-03-31
IL245255B (en) 2020-02-27
US20160264953A1 (en) 2016-09-15
HUE055236T2 (hu) 2021-11-29
PH12016500708A1 (en) 2016-05-30
IL245255A0 (en) 2016-06-30
EP3060660A2 (en) 2016-08-31
HRP20211197T1 (hr) 2021-11-12
CN112852784A (zh) 2021-05-28
TW202332774A (zh) 2023-08-16
IL272609B (en) 2022-03-01
KR20210111880A (ko) 2021-09-13
WO2015061464A2 (en) 2015-04-30
SG11201602932WA (en) 2016-05-30
JP6837334B2 (ja) 2021-03-03
AU2014340152A1 (en) 2016-06-09
KR102298080B1 (ko) 2021-09-06
TW201900873A (zh) 2019-01-01
UA119857C2 (uk) 2019-08-27
CN114606217A (zh) 2022-06-10
KR102479886B1 (ko) 2022-12-20
EP3060660B1 (en) 2021-06-23
PT3060660T (pt) 2021-08-06
DK3060660T3 (da) 2021-09-13
EP3778884A1 (en) 2021-02-17
SI3060660T1 (sl) 2021-09-30
CN105916984A (zh) 2016-08-31
BR112016008086A2 (pt) 2017-10-03
TWI642782B (zh) 2018-12-01
SG10201803366PA (en) 2018-05-30
TW201610163A (zh) 2016-03-16
RS62171B1 (sr) 2021-08-31
EA201690826A1 (ru) 2016-08-31
EA034515B1 (ru) 2020-02-14
PE20160723A1 (es) 2016-08-01
JP7296327B2 (ja) 2023-06-22
MY197247A (en) 2023-06-08
JP2020089379A (ja) 2020-06-11
CR20160225A (es) 2016-06-24
PL3060660T3 (pl) 2021-12-06
ES2882562T3 (es) 2021-12-02
LT3060660T (lt) 2021-07-26
KR20160066550A (ko) 2016-06-10
UY35794A (es) 2015-05-29
NZ720384A (en) 2022-04-29
JP2016538840A (ja) 2016-12-15
CL2016000961A1 (es) 2017-02-03
AU2020294173A1 (en) 2021-02-11
WO2015061464A3 (en) 2015-09-03
CA2927852A1 (en) 2015-04-30
MX2016005321A (es) 2017-01-05
MY178632A (en) 2020-10-19
TN2016000140A1 (en) 2017-10-06
TWI793159B (zh) 2023-02-21
US11208644B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
UY37463A (es) Proteínas de unión
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
CO2020013588A2 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CL2018000302A1 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CL2018000750A1 (es) Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
DOP2016000079A (es) Glicoproteinas recombinantes y sus usos
GT201200252A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
BR112016014876A2 (pt) composto que modula a quantidade ou a atividade de gibspla2, composição farmacêutica, imunógeno que induz uma resposta imune anti-gibspla2, composição de vacina, método para o diagnóstico da imunodeficiência humana associada com a alteração de células t, e, método para a produção de gibspla2
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
PH12019500949A1 (en) Ror-gamma modulators
BR112017013574A2 (pt) conjugados de aminoácido e peptídeo e usos dos mesmos
BR112019000837A2 (pt) células miméticas de célula b
CL2019002155A1 (es) Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.